Recombinant Proteins Market Size to Hit Around USD 5.33 BN by 2030

According to Latest Report Study, the global recombinant proteins market size is projected to hit around USD 5.33 billion by 2030 and growing at a CAGR of 12.82% from 2022 to 2030.

Report Highlights

• The product segment dominated the global industry in 2021. The segment accounted for the highest share of more than 65.8% of the overall revenue in the same year. 
• The therapeutics segment dominated the global industry in 2021 and accounted for the maximum share of more than 33.95% of the overall revenue. 
• The mammalian host cell segment dominated the global industry in 2021 and accounted for the highest revenue share of more than 41.8% of the overall revenue. 
• The pharma & biotech companies segment captured the highest revenue share in 2021. The segment is estimated to expand further at the fastest CAGR during the forecast period.
• North America dominated the global industry in 2021 and accounted for the maximum share of more than 33.9%.

Immediate Delivery Available | Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/39752

Diseases like multiple sclerosis, neutropenia, cerebral apoplexy, anemia, and others, as well as dwarfism, are becoming more common, which is driving up the demand for recombinant protein drugs. Furthermore, the industry is anticipated to expand due to the increased development and research on biologics, which, in turn, are significantly boosting global industry growth. The focus on the development of biosimilars, biologics, and recombinant proteins has increased owing to a rise in the incidence and prevalence of cancer and the expansion of research & development activity.

According to the American Cancer Society, in 2022, there will be 1.9 million new cancer cases and 609,360 cancer-related deaths. In addition, the expanding application of recombinant proteins in clinical diagnostic methods including ELISA, Western Blotting, and Immunohistochemistry (IHC) is anticipated to fuel market expansion. Due to factors including rising R&D spending, an increase in the number of cancer patients, and the desire for novel & tailored therapies, the global industry is anticipated to expand significantly during the forecast period. Research activity in recombinant protein space has increased in response to the COVID-19 pandemic as a result of efforts to comprehend the dynamics of the virus. The production of recombinant proteins has increased significantly, along with tailored treatment.

In addition, research funding is predicted to become more readily available along with an increase in demand for and production of recombinant proteins, particularly those immune response proteins associated with COVID-19. Therefore, positive effects have been seen for the companies offering products specifically made for COVID-19. Recombinant protein is viewed as a modified version of natural protein that can be produced in a number of ways to improve protein output, create useful commercial goods, and alter gene sequences. The main drivers of the global industry are the rise in pharmaceutical firms’ R&D expenditures, high incidence of chronic illnesses, an increase in the number of regulatory requirements, and the ongoing need to reduce viral infections.

Over the projected period, the global industry is anticipated to be driven by technological advancements in the synthesis of recombinant proteins. For instance, in June 2022, according to the data produced by the National Center for Biotechnology Information, new breeding techniques, such as CRISPR/Cas9, TALEN, and Zinc Finger mediated, as well as transgenic or cis-genic techniques, are emerging technologies that may make it easier for in vitro genetic editing or manipulation of the genes to be approved. In addition, industry participants are anticipated to invest in the region due to the aging population, rising income levels, better healthcare infrastructure, rising healthcare spending, and the advantages of low-cost manufacturing in developing nations, thereby propelling market growth.

Scope of The Report

Key Market Trends

The Antibody Segment is Expected to Grow at the Fast Rate Over the Forecast Period

The recombinant antibody production procedure involves cloning antibody gene libraries into phage vectors and allowing the phages to infect a host cell line. The host cells then produce daughter phages expressing the recombinant antibodies on their surfaces. The genes can be inserted into an expression system, and the antibodies can be produced in large quantities after a process of selection for antibodies with the desired characteristics.

Collaboration among the market players and research institutes is also expected to propel the growth of the market segment. For instance, in June 2020, the Recombinant Antibody Network (RAN), a consortium comprising research groups from UC San Francisco, the University of Chicago, and the University of Toronto, entered into a research collaboration with Celgene, a Bristol Myers Squibb company, to create and develop high-performance recombinant antibodies against diverse targets in human cells.

Companies are also involved in the development of recombinant antibodies for COVID-19 infection. For instance, in February 2021, Sanofi and GSK initiated a new phase 2b study with 720 volunteers aged 18 and over to select the most appropriate antigen dosage for phase 3 evaluation of the adjuvanted recombinant protein COVID-19 vaccine candidate. Also, in September 2020, GigaGen Inc., in collaboration with Waisman Biomanufacturing and Goodwin Biotechnology Inc., initiated large-scale manufacturing of its first-in-class recombinant hyperimmune drug GIGA-2050 for the treatment of COVID-19.

Hence, the aforementioned factors are expected to drive market growth in this segment.

Product & Services Insights

The product segment dominated the global industry in 2021. The segment accounted for the highest share of more than 65.8% of the overall revenue in the same year. The segment is anticipated to expand further at the second-fastest growth rate maintaining the leading position throughout the forecast period. The growth of this segment is a result of the extensive product usage in the fields of cancer, HIV/AIDS, COVID-19, immunology, and neuroscience, among others. Furthermore, growth factors and cytokines play a significant role in cancer research.

Study regarding the usage of growth factors in the treatment of cancer has improved the understanding and has given rise to new goals for chemotherapy. In addition, the need for recombinant protein products in regenerative medicine as well as rising financing for research & development in the fight against cancer are driving up the demand across the globe. On the other hand, the services segment has been estimated to register the fastest growth rate during the forecast period.

Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/39752

Application Insights

The therapeutics segment dominated the global industry in 2021 and accounted for the maximum share of more than 33.95% of the overall revenue. The segment is also estimated to register the fastest growth rate during the forecast period. The demand for protein-based treatment is anticipated to rise as the prevalence of diseases, such as metabolic disorders, cancer, genetic disorders, and immune diseases rises. In addition, cancer is one of the leading causes of mortality globally, and the World Health Organization (WHO) predicts a significant rise in cancer cases in the coming years.

As a result, it is projected that the industry for therapeutics would experience growth. On the other hand, protein therapeutics offer highly effective treatments for illnesses like diabetes, cancer, infectious disorders, hemophilia, and anemia. As per the International Diabetes Federation, 537 million persons (20-79 years old) are estimated to have diabetes in 2021. According to projections, there would be 643 million diabetics worldwide by 2030 and 783 million by 2045. With such growth in the diabetic population, the demand for recombinant proteins in the therapeutics segment is likely to show lucrative growth in the coming years.

Host Cell Insights

On the host cells, the global industry has been further categorized into mammalian systems, insect cells, yeast & fungi, bacterial cells, and others. The mammalian host cell segment dominated the global industry in 2021 and accounted for the highest revenue share of more than 41.8% of the overall revenue. The segment is estimated to expand further at the fastest growth rate maintaining its leading industry position throughout the forecast period. Mammalian protein expression is becoming increasingly popular as the market for proteomics & biologics expands.

Since they are provided easily, protein expression systems are simple to include in high throughput systems for effective biologics and proteomics investigations. Moreover, the focus on producing biopharmaceutical goods has increased as a result of factors, such as the rising incidence and prevalence of cancer and rising research & development (R&D) efforts, which are driving the industry expansion. The bacterial cells segment is estimated to register the second-fastest growth rate during the forecast period.

End-user Insights

The pharma & biotech companies segment captured the highest revenue share in 2021. The segment is estimated to expand further at the fastest CAGR during the forecast period retaining its leading position. The inclination toward biologics and biosimilars has resulted in a cascade of multi-million investments by the bio-manufacturers in R&D for growing the pipeline of products, devising new technologies, and advancing bioprocessing tools. The increasing demand, rising competition among players, and various applications by end-users have also attributed to the advancements in recombinant protein products.

In addition, the R&D sector also witnessed increased investments in terms of collaboration & partnerships between academia and industries. For example, Pfizer’s Center for Therapeutic Innovation (CTI) is a platform for collaboration within the healthcare ecosystem. CTI actively collaborates with academic institutes and investigators to tackle the challenges using Pfizer’s concepts. Collaborations like these fuel the drug development research and potential therapies for patients eventually propelling the industry growth.

Regional Insights

North America dominated the global industry in 2021 and accounted for the maximum share of more than 33.9% due to the rising research spending, availability of healthcare infrastructure, and presence of a number of industry players. In addition, recombinant proteins are one of the tested treatments for such disorders, therefore the chronic diseases that are spreading throughout the region are producing high demand for recombinant protein therapies. As per the GLOBOCAN estimates, in Mexico, in 2020, there were 90,222 cancer-related deaths and 1,95,499 newly diagnosed cancer cases.

To combat the pandemic, a number of major pharmaceutical companies in the U.S. have made investments in recombinant DNA technology and proteins. In April 2020, Sanofi & GSK collaborated on the development of vaccines using GSK’s additive technique as well as Sanofi’s recombinant S-protein COVID-19 antigens. In addition, several acquisitions are taking place to advance R&D for the production of recombinant proteins. The Asia Pacific region is also expanding due to an increase in public and private funding for research and development for recombinant protein studies, favorable government regulations, and the rising prevalence of target diseases with an aging population. In addition, the development of advanced techniques in proteomic and genomic research is propelling the region’s growth.

Key Players

• Abcam plc.
• Sino Biological, Inc.
• R&D Systems, Inc.
• GenScript
• Bio-Rad Laboratories, Inc.
• Merck KGaA
• Thermo Fisher Scientific
• Proteintech Group, Inc.
• Enzo Life Sciences, Inc. 
• Abnova Corp.
• RayBiotech Life Inc.
• STEMCELL Technologies Inc.

Market Segmentation

• By Product & Services Scope Outlook
  • Product
    • Cytokines & Growth Factors
      • Interferons (IFNs)
      • Interleukins (ILs)
      • Others
    • Antibodies
    • Immune Checkpoint Proteins
    • Virus Antigens
    • Enzymes
      • Kinases
      • Metabolic enzymes
      • Others
    • Recombinant Regulatory Protein
    • Hormones
    • Others
  • Production Services
• By Application Scope Outlook
  • Drug Discovery & Development
  • Therapeutics
    • Biologics
    • Vaccines
    • Cell & Gene Therapies
    • Others
  • Research
  • Others
• By End-user Scope Outlook
  • Pharma & Biotechnology Companies
  • Academic & Research Institutes
  • Diagnostic Laboratories
  • Others
• By Host Cell Scope Outlook
  • Mammalian Systems
  • Insect Cells
  • Yeast & Fungi
  • Bacterial Cells
  • Others
• By Regional Scope Outlook
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Click Here to View Full Report Table of Contents

Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/39752

You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333

Blog: https://www.novaoneadvisor.com/

Blog: https://qyresearchmedical.com/